Endoscopic Retrograde Cholangiopancreatography Market Outlook by Product Type (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices), Application (Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation, Pancreatic Duct Stenting), End User (Hospitals & Clinics, Ambulatory Surgery Centers) – Global Industry Revenue Estimation and Demand Forecast to 2030

Market Overview

The global endoscopic retrograde cholangiopancreatography market size stood at $1,270.9 million in 2021, which is expected to reach $2,557.7 million by 2030, advancing at a CAGR of 8.1% during 2021–2030. This is mainly ascribed to the rise in the prevalence of pancreatic cancer and a paradigm shift toward minimally invasive procedures.

Moreover, the inclusion of health coverage such as health insurance for ERCP procedures in certain countries also fuels the market growth. For instance, an average endoscopy procedure costs more than $3,000 in the U.S., but due to the inclusion of health insurance, the cost can decrease up to $1,500.

Endotherapy Devices Are the Highest Revenue Generator

Endotherapy devices and endoscopes collectively held around 70% share in 2021, with the former accounting for about 40%. This is attributed to the increase in demand for ERCP devices coupled with the high incidence of pancreatitis, pancreatic cancer, gallbladder stones, and choledocholithiasis. As per the American Health Organization, more than 60,000 people are estimated to have suffered from pancreatic cancer in 2022, and around 50,000 people will die from it, in the U.S.

Considering the importance of sphincterotomes in the market, prominent players have actively participated in the launch of various products, such as TRUEtome cannulating sphincterotome by Boston Scientific Corporation, CleverCut3V line of sphincterotomes by Olympus Corporation, and D.A.S.H Sphincterotome with DomeTip by Cook Group Incorporated, which has resulted in the high share of sphincterotome in the endotherapy devices market.

The endoscopes category accounted for the second-largest share, of around 30%, in 2021, due to the spur in cases of chronic biliary and GI diseases. For instance, more than 20 million Americans were suffering from chronic digestive disorders in 2021. In addition, companies are strenuously participating in the launch of various endoscopes, which is causing remunerative opportunities for the market. For instance, in January 2022, Cook Group Incorporated announced the launch of an endoscopic clipping device, Instinct Plus, in the U.S. This device provides firm clip retention and smooth handling with a duodenoscope for prophylactic clipping in the GI tract.

ERCP Devices Are Highly Used in Biliary Sphincterotomy Application

Among all applications, the biliary sphincterotomy category accounted for the highest revenue share, of around 45%, in the endoscopic retrograde cholangiopancreatography market in 2021. This is on account of the high use of ERCP devices in the treatment of bile obstruction, common bile duct stones, tissue sampling, and stent placement. For instance, the incidence of intrahepatic bile duct cancer is around 10 per 100,000 men and women annually, in the U.S.

Hospitals & Clinics Category To Witness the Highest CAGR

Hospitals & clinics are the largest end users of ERCP, and the category is expected to record the highest CAGR, of around 8.3%, in the forecast period. This can be ascribed to the rising number of trained and accredited endoscopists, such as gastroenterologists or surgeons, a spur in the number of hospitals, and the majority of endoscopic diagnosis interventions performed in these healthcare facilities. Also, the same-day surgical care comprising both preventive and diagnostic procedures offered by various clinics drives the market growth in this category.

Rising Prevalence of Pancreatic Cancer Driving the North American Market

In 2021, the North American endoscopic retrograde cholangiopancreatography market accounted for the highest revenue, of around $471.4 million, in 2021. Around 3% of deaths in the U.S. region occur due to pancreatic cancer every year. Moreover, the rising consumption of alcohol is leading to several diseases such as pancreatic neuroendocrine tumor (PanNET) and pancreatic adenocarcinoma. These factors are resulting in the high usage of ERCP procedures in the region. In addition, more than 20% of the Canadian population suffers from bile duct disease, which is further driving the market growth.

Additionally, the approval of various ERCP devices by the FDA in the region also intensifies the market growth. For instance, in July 2020, Ambu Inc. received the FDA approval for Ambu aScope Duodeno, which is a sterile, single-use duodenoscope.

Whereas, the APAC market is expected to register the fastest growth, propelling at a CAGR of 8.5%, during the forecast period. This can be attributed to the increasing patient awareness regarding ERCP devices coupled with the rising prevalence of GERD and pancreatic cancer, in the region. Moreover, the surging government initiatives and awareness programs toward bile duct cancer, pancreatic conditions, and related complications are expected to propel the demand for ERCP devices in APAC.

Furthermore, Japan and China collectively accounted for around 60% share of the regional market in 2021. This is due to the high incidence of GI-related cancers in both countries. For instance, as per a government organization, there were around 3,00,000 GI-related cancer deaths in China in 2021, which accounts for more than 13% of all cancer-related deaths in the nation.

Explore more about this report - Request free sample

Recent Strategic Developments of Key Players

In recent years, players operating in the endoscopic retrograde cholangiopancreatography market have been involved in acquisitions, product launches, and partnerships, in order to attain a significant position. For instance:

• In January 2021, STERIS plc announced the acquisition of Cantel Medical Corp., which provides infection preventive products and services to endoscopy customers. This acquisition would expand the product portfolio of STERIS in different geographical areas.
• In March 2021, Fujifilm Holdings Corporation announced the acquisition of the diagnostic imaging-related business of Hitachi Ltd., to strengthen its healthcare business.

Key Players in the Market for ERCP Devices Are:

• Olympus Corporation
• CONMED Corporation
• Fujifilm Holdings Corporation
• HOYA Corporation
• KARL STORZ SE & Co. KG
• Ambu A/S
• Boston Scientific Corporation
• Johnson & Johnson Private Limited
• Medtronic Private Limited
• Cook Group Incorporated
• B. Braun Melsungen AG.

ERCP Market Size Breakdown by Segment

The study offers comprehensive market segmentation analysis along with market estimation for the period 2017-2030.

Based on Product Type

• Endoscopes
• Endotherapy Devices
  • Sphincterotome
  • Lithotripter
  • Stents
  • Cannulas
  • Forceps
  • Snares
  • Catheters
  • Guiding Wires
  • Balloons
  • Baskets
• Visualization Systems
• Energy Devices

Based on Application

• Biliary Sphincterotomy
• Biliary Dilatation
• Biliary Stenting
• Pancreatic Sphincterotomy
• Pancreatic Duct Dilatation
• Pancreatic Duct Stenting

Based on End User

• Hospitals & Clinics
• Ambulatory Surgery Centers

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific (APAC)
  •  China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America (LATAM)
  • Brazil
  • Mexico
• Middle East and Africa (MEA)
  • Saudi Arabia
  • South Africa